Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints

Abstract

Significance Breast cancer (BrCa) is the most common cancer worldwide, and high-performance metabolic analysis is emerging in diagnosis and prognosis of BrCa. Here, we used nanoparticle-enhanced laser desorption/ionization mass spectrometry to record serum metabolic fingerprints of BrCa in seconds, achieving high reproducibility and low consumption of direct serum detection. Our analytical method, combined with the aid of machine learning algorithms, was demonstrated to provide high diagnostic efficiency with accuracy of 88.8% and desirable prognostic prediction ( P < 0.005). Furthermore, seven metabolic biomarkers differentially enriched in BrCa serum and their related pathways were identified. Together, our findings provide a tool to characterize BrCa and highlight certain metabolic signatures as potential diagnostic and prognostic factors of diseases including but not limited to BrCa.

Establishment and Analysis of an Individualized EMT-Related Gene Signature for the Prognosis of Breast Cancer in Female Patients

“…BC is one of the most common cancers in females, with over 1,300,000 new cases and 450,000 deaths worldwide each year [ 16 , 17 ]. Treatment of BC has advanced considerably, mainly through surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy, systemic therapy, targeted therapy, and so on, with initial conventional surgery no longer being the best option for all patients [ 1 ].…”

MALDI-TOF Mass Spectrometry in Clinical Analysis and Research

“… In the presence of high concentrations of co-occurring peptides and proteins, only Na + - and K + -coupled metabolites can be detected using the vanadium core–shell nanorods. More recently, the same group also reported the high performance of nanoparticle-enhanced laser desorption/ionization mass spectrometry (NPELDI-MS) in differentiating between breast and nonbreast cancers with an area under the receiver operating characteristic curve of 0.948 . Wang et al assembled gold nanoparticle arrays at the liquid–liquid interface to assist LDI MS with high desorption efficacy and reproducibility in quantification (RSD < 5%) that can be used to quantify glucose in the cerebrospinal fluid, allowing rapid identification of patients with brain infections .…”

“…More recently, the same group also reported the high performance of nanoparticle-enhanced laser desorption/ ionization mass spectrometry (NPELDI-MS) in differentiating between breast and nonbreast cancers with an area under the receiver operating characteristic curve of 0.948. 116 Wang et al assembled gold nanoparticle arrays at the liquid−liquid interface to assist LDI MS with high desorption efficacy and reproducibility in quantification (RSD < 5%) that can be used to quantify glucose in the cerebrospinal fluid, allowing rapid identification of patients with brain infections. 117 The LDI MSbased small molecule applications in biofluid profiling have similarities with section 4.2 of this review.…”

Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry

“…Mass spectrometry (MS) is a powerful method for profiling metabolic fingerprints of biofluids . Combined with machine learning, MS-based methods show appealing performance in the diagnosis of gynecological cancers, gastric cancer, lung adenocarcinoma, and breast cancer . MS has also been used for investigating the relationship between BC and urine metabolites. − For instance, BC has been analyzed by metabolomic profiling of urine by high-performance liquid chromatography MS (HPLC-MS) coupled with orthogonal partial least squares-discriminant analysis (OPLS-DA) and two-dimensional gas chromatography time-of-flight (GC × GC-TOF MS) .…”